- Home
- BCAX vs XNCR Comparison
BCAX vs XNCR Comparison
Compare BCAX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- XNCR
- Stock Information
- Founded
- BCAX 2018
- XNCR 1997
- Country
- BCAX United States
- XNCR United States
- Employees
- BCAX N/A
- XNCR N/A
- Industry
- BCAX
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- BCAX
- XNCR Health Care
- Exchange
- BCAX NYSE
- XNCR Nasdaq
- Market Cap
- BCAX 487.6M
- XNCR 579.3M
- IPO Year
- BCAX 2024
- XNCR 2013
- Fundamental
- Price
- BCAX $9.71
- XNCR $8.80
- Analyst Decision
- BCAX Strong Buy
- XNCR Buy
- Analyst Count
- BCAX 7
- XNCR 7
- Target Price
- BCAX $29.17
- XNCR $27.50
- AVG Volume (30 Days)
- BCAX 675.0K
- XNCR 788.7K
- Earning Date
- BCAX 08-16-2025
- XNCR 08-04-2025
- Dividend Yield
- BCAX N/A
- XNCR N/A
- EPS Growth
- BCAX N/A
- XNCR N/A
- EPS
- BCAX N/A
- XNCR N/A
- Revenue
- BCAX N/A
- XNCR $127,228,000.00
- Revenue This Year
- BCAX N/A
- XNCR N/A
- Revenue Next Year
- BCAX N/A
- XNCR $28.84
- P/E Ratio
- BCAX N/A
- XNCR N/A
- Revenue Growth
- BCAX N/A
- XNCR N/A
- 52 Week Low
- BCAX $7.80
- XNCR $7.16
- 52 Week High
- BCAX $28.09
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- XNCR 54.21
- Support Level
- BCAX N/A
- XNCR $7.93
- Resistance Level
- BCAX N/A
- XNCR $9.48
- Average True Range (ATR)
- BCAX 0.00
- XNCR 0.52
- MACD
- BCAX 0.00
- XNCR 0.11
- Stochastic Oscillator
- BCAX 0.00
- XNCR 73.21
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.